No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou
Homayoon
H
Sayana
Shilpa
S
Acosta
Edward
E
D000225:Adenine / Q000031:analogs & derivatives; D019380:Anti-HIV Agents / Q000008:administration & dosage; D024882:Drug Resistance, Viral / Q000235:genetics*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019427:HIV Integrase / Q000235:genetics*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D009154:Mutation; D063065:Organophosphonates; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000494:pharmacology*; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage; D000068698:Tenofovir; D019562:Viral Load
D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D011760:Pyrrolidinones; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D019427:HIV Integrase; D000225:Adenine; D019438:Ritonavir